Chi-Med gains scientific advice & plans to submit MAA for surufatinib

Date: 2020-08-11   Author: Saipriya Iyer  Category: #news

Chi-Med gains scientific advice & plans to submit MAA for surufatinib

Hutchison China MediTech Ltd. (Chi-Med) has recently received scientific advice from the EMA (European Medicines Agency’s) CHMP (Committee for Medicinal Products for Human Use). This scientific advice is related to surufatinib, an angio-immuno kinase inhibitor, used for the treatment of patients suffering from advanced NET (neuroendocrine tumors).

Chi-Med, based on the advice of CHMP, has concluded that the completed non-pancreatic NET (SANET-ep) and pancreatic NET (SANET-p) studies, in addition to the available data from the surufatinib studies among the pancreatic and non-pancreatic NET patients in the U.S., could form a basis for submitting the MAA (marketing authorization application). Due to the identification of no filing issues, the company is likely to submit the MAA in 2021, following the submission of the NDA (new drug application) to the U.S. FDA (Food & Drug Administration).

Surufatinib selectively inhibits tyrosine kinase activity that is associated with FGFR (fibroblast growth factor receptor) and VEGFR (vascular endothelial growth factor receptor), which inhibit angiogenesis, & CSF-1R (colony stimulating factor-1 receptor), which regulates the tumor-associated macrophages. This promotes the immune response of the body against the tumor cells. The unique dual mechanism of action of this inhibitor is anticipated to be suitable for its combinations with other immunotherapies. This may lead to the development of synergistic anti-tumor effects.

Moreover, Chi-Med has currently retained all rights to this inhibitor across the globe.

In April 2020, surufatinib was granted the Fast Track Designations for the development of non-pancreatic and pancreatic (extra-pancreatic) NET in the United States. Additionally, in November 2019, it was granted the Orphan Designation for the treatment of pancreatic NET. The company has also entered various collaboration agreements to examine the safety, efficacy, and tolerability of surufatinib, by combining with anti-PD-1 monoclonal antibodies, including tislelizumab, Tuoyi®, and Tyvyt®. These antibodies are currently approved for use in China.

Source credit:

https://www.benzinga.com/pressreleases/20/08/g17003996/chi-med-plans-to-submit-marketing-authorization-application-for-surufatinib-following-scientific-a



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Intelligent Process Automation(IPA) Market Covid-19 Impact In-Depth Industry Analysis 2026

Author: Ashwin Naphade

The research report on Intelligent Process Automation(IPA) market offers critical information such as the development trends, restraints, CAGR, revenue prospects, product type, application scope, competitive scenario, and COVID-19 impact.

<...


Passive Optical LAN (POL) market players to make profitable investments during 2021-2026

Author: Ashwin Naphade

Global Passive Optical LAN (POL) Market Report provides complete industry analysis, market outlook, size, growth, opportunities and forecast 2026. This report will assist in analyzing the current and future business trends, sales and revenue forec...


Research on Intelligent Machine Control System Market 2021: By Growing Rate, Type, Applications, Geographical Regions, and Forecast to 2026

Author: Ashwin Naphade

Intelligent Machine Control System market report is a comprehensive analysis of the growth dynamics and revenue inflows in this industry sphere over 2021-2026, inclusive of Covid-19 impact.

The latest research report on Intelligent Machi...